Evercore ISI analyst Liisa Bayko maintained a Buy rating on Innate Pharma (IPHA – Research Report) today and set a price target of $5.00.
15hon MSN
Krishna Guha, Evercore ISI vice chairman, joins CNBC's 'Squawk Box' to discuss expectations for PPI, how a new Trump ...
NEW YORK (Reuters) - Evercore ISI on Wednesday forecast the S&P 500 will rise to 6,600 by mid-2025, saying a "decisive and ...
Evercore ISI reiterated an Outperform rating and $22 price target on Bloom Energy (BE) after American Electric Power (AEP) said it has an ...
Artisan Partners Asset Management (NYSE:APAM – Free Report) had its target price boosted by Evercore ISI from $40.00 to $44.00 in a report published on Thursday,Benzinga reports.They currently ...
On October 23, Evercore ISI raised the price target on the stock to $323 from $300 and kept an Outperform rating on the ...
Evercore ISI revised its ratings for several industrial and machinery stocks following the US election results, citing a more optimistic business outlook tied to the anticipated "pro-business Trump" ...
The S&P 500 is poised for continued growth into mid-2025 after Trump's victory: Evercore ISI The stock-market rally still has room to run, as Donald Trump's stunning comeback for the White House ...
NEW YORK, October 29, 2024--(BUSINESS WIRE)--Evercore ISI was ranked No. 1 among all firms for top-ranked analysts on a weighted basis in Extel’s (previously Institutional Investor) All-America ...
Evercore ISI analyst Thomas Gallagher upgraded Prudential (PRU) to In Line from Underperform with a price target of $140, up from $117. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback